Anti-Human VEGF Recombinant Antibody (Bevacizumab)
Creative BiolabsRecombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney, and ovarian. Bevacizumab is a humanized monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).